相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Synthesis and evaluation of sulfonamide derivatives targeting EGFR790M/L858R mutations and ALK rearrangement as anticancer agents
Longcai Cao et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2023)
Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: From theory to therapy
Ruoyu Guo et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2023)
The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection
Swati G. Patel et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma
Karen Xu et al.
TOMOGRAPHY (2022)
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma
Patrick B. Johnston et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)
Recent developments of HDAC inhibitors: Emerging indications and novel molecules
Andrey D. Bondarev et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Risk of Colorectal Carcinoma May Predispose to the Genetic Variants of the GST, CYP450, and TP53 Genes Among Nonsmokers in the Saudi Community
Ikhlas A. Sindi et al.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2021)
Vorinostat and Belinostat, hydroxamate-based anti-cancer agents, are nitric oxide donors
Reece G. Kenny et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2020)
17-AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA-MB-231 breast cancer cells
Yu Zuo et al.
ONCOLOGY REPORTS (2020)
Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy
Gloria Manzotti et al.
CANCERS (2019)
A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction
Naoko Takebe et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial
Thehang Luu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model
Diana Llopiz et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Histone Deacetylase Inhibitors as Anticancer Drugs
Tomas Eckschlager et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinoma
Li R. Kong et al.
MOLECULAR ONCOLOGY (2017)
Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1
Lingzhi Wang et al.
ONCOTARGET (2017)
Enhanced anti-tumor efficacy of a checkpoint inhibitor in combination with the HDAC inhibitor belinostat in a murine hepato-cellular carcinoma preclinical model
Diana Llopiz et al.
CANCER RESEARCH (2017)
A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin
Neeraj Agarwal et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma
Aaron P. Havas et al.
CANCER BIOLOGY & THERAPY (2016)
A novel combinatorial strategy using Seliciclib® and Belinostat® for eradication of non-small cell lung cancer via apoptosis induction and BID activation
Pei-Shi Ong et al.
CANCER LETTERS (2016)
Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor - belinostat - in glioblastoma cell lines: a preliminary report
Magdalena Kusaczuk et al.
INVESTIGATIONAL NEW DRUGS (2016)
The TEAD Family and Its Oncogenic Role in Promoting Tumorigenesis
Yuhang Zhou et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Hyon-Zu Lee et al.
CLINICAL CANCER RESEARCH (2015)
Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling
Giedre Valiuliene et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2015)
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combination Treatment of Renal Cell Carcinoma with Belinostat and 5-Fluorouracil: A Role for Oxidative Stress Induced DNA Damage and HSP90 Regulated Thymidine Synthase
Mi Joung Kim et al.
JOURNAL OF UROLOGY (2015)
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma
Francine Foss et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells
Jurate Savickiene et al.
ANTI-CANCER DRUGS (2014)
A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study
Anish Thomas et al.
CLINICAL CANCER RESEARCH (2014)
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Edward Seto et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer
Dmitriy I. Dovzhanskiy et al.
BMC CANCER (2012)
Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours
R. Pili et al.
BRITISH JOURNAL OF CANCER (2012)
Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group
Winnie Yeo et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene
Koichi Hirose et al.
ONCOLOGY LETTERS (2012)
Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors
Giuseppe Giaccone et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma
Luca Paoluzzi et al.
CLINICAL CANCER RESEARCH (2010)
Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostat
Hans Christian Beck et al.
ELECTROPHORESIS (2010)
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours
Helen J. Mackay et al.
EUROPEAN JOURNAL OF CANCER (2010)
A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors
Nicola L. Steele et al.
CLINICAL CANCER RESEARCH (2008)
A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia
Peter Gimsing et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer
Xiaozhong Qian et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
Michael T. Buckley et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Pharmacogenetics of irinotecan metabolism and transport: An update
NF Smith et al.
TOXICOLOGY IN VITRO (2006)
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma:: a study by the EORTC Soft Tissue and Bone Sarcoma Group
I Judson et al.
EUROPEAN JOURNAL OF CANCER (2001)
分享论文
